Protein C and coagulation in sepsis;La proteina C e la coagulazione nella sepsi

Minerva Anestesiologica

Volumn 70, Issue 5, 2004, Pages 339-350

  D'Angelo, Armando ^a   Della Valle, P ^a   Giudici, D ^a   D'Angelo, S Viganò ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Inflammation; Protein C; Sepsis

Indexed keywords

ACTIVATED PROTEIN C; ACUTE PHASE PROTEIN; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; ANTITHROMBIN; CYTOKINE; DROTRECOGIN; HEPARIN; PROCOAGULANT; PROTEIN C; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; THROMBIN; THROMBOPLASTIN; TUMOR NECROSIS FACTOR ANTIBODY;

ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD CLOTTING; CELL MEMBRANE; CELL PROLIFERATION; CYTOKINE PRODUCTION; ENDOTHELIUM LESION; FEEDBACK SYSTEM; FIBRIN DEPOSITION; FIBRINOLYSIS; HUMAN; IMMUNOMODULATION; INFLAMMATION; ISCHEMIA; LEUKOCYTE ACTIVATION; MEDIATOR RELEASE; MICROCIRCULATION; MONOCYTE; MULTIPLE ORGAN FAILURE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SEPSIS; SURVIVAL; THROMBOCYTE ACTIVATION; THROMBOSIS; VASCULAR ENDOTHELIUM;

ANIMALS; BLOOD COAGULATION; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION; PROTEIN C; SEPSIS; SEVERITY OF ILLNESS INDEX;

EID: 3142715350     PISSN: 03759393     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Matot I, Sprung CL. Definition of sepsis. Intensive Care Med 2001;27:S3-S9.
2. Salvo I, de Cian W, Musico M, Langer M, Piadena R, Wolfler A,et al.. The Italian Sepsis Study: preliminary results on the incidence and evolution of SIRS, severe sepsis and septic shock. Intensive Care Med 1995;21:S244-S249.
3. Fumagalli R. Personal communication.
4. Wenzel RP. Treating sepsis. N Engl J Med 2002;347:966-7.
5. Friedman G, Silva E, Vincent JL. Has the mortality of septic shock changed with time ? Crit Care Med 1998;26:2078-86.
6. Buzan J. Structural design and molecular evaluation of a cytokine receptor family. Proc Natl Acad Sci USA 1990;87:6934-8.
7. Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 2003;101:3765-77.
8. Rosenberg RD. Vascular-bed specific hemostasis and hypercoagulable states. N Engl J Med 1999;340:1555-64.
9. Ikeda K, Stenflo J. A radioimmunoassay for protein C. Thromb Res 1985;39:297-306.
10. Esmon CT. The protein C pathway. Crit Care Med 2000;28:S44-S48.
11. Mosnier LO, Meijers JC, Bouma BN. Protein C inhibitor regulates the thrombin-thrombomodulin complex in the up- and down regulation of TAFI activation. Thromb Haemost 2001;86:1057-64.
12. Creasey AA, Stevens P, Kenney J, Allison AC, Warren K, Catlett R, et al.. Endotoxin and cytokine profile in plasma of baboons challenged with lethal and sublethal Escherichia Coli. Circ Shock 1991;33:84-91.
13. Taylor FB Jr, Chang AC, Esmon CT, Hinshaw LB. Baboon model of Escherichia Coli sepsis: description of its four stages and the role of tumor necrosis factor, tissue factors, and the protein C system in septic shock. Curr Stud Hematol Blood Trasfus 1991;58:8-14.
14. Taylor FB Jr, Chang AC, Peer GT, Mather T, Blick KE, Catlett R et al. DEGR-factor Xa blocks disseminated intravascular coagulation initiated by Escherichia Coli without preventing shock or organ damage. Blood 1991;78:364-8.
15. Taylor FB Jr, Chang AC, Peer G, Li A, Ezhan M, Hedner U. Active site inhibited factor VIIa (DEGR VIIa) attenuates the coagulant and dinterelukin-6 and -8, but not tumor necrosis factor, responses of the baboon to LD 100 Escherichia coli. Blood 1998;91:1609-15.
16. Taylor FB Jr, Chang A, Hinshaw LB, Esmon CT, Archer LT, Beller BK. A model for thrombin protection against endotoxin. Thromb Res 1984;36:177-85.
17. Taylor FB Jr, Chang A, Esmon CT, D'Angelo A, Viganò-D'Angelo S, Blick KE. Protein C prevents the coagulopathic and lethal effects of E.Coli infusion in the baboon. J Clin Invest 1987;79:918-25.
18. Taylor FB Jr, Dahlback B, Chang AC, Lockhart MS, Hatanaka K, Peer G et al. Role of free protein S and C4b binding protein in regulating the coagulant response to Escherichia coli. Blood 1995;86:2642-52.
19. Taylor FB Jr, Stearns-Kurosawa DJ, Kurosawa S, Ferrell G, Chang AC, Laszik Z et al. The endothelial protein C receptor aids in host defense against Escherichia coli sepsis. Blood 2000;95:1680-6.
20. Weiler H, Lindner V, Kerlin B, Isermann BH, Hendrickson SB, Cooley BC, et al.. Characterization of a mouse model for thrombomodulin deficiency. Arterioscl Thromb Vasc Biol 2001;21:1531-7.
21. Weiler-Guettler H, Christie PD, Beeler DL, Heally AM, Hancock WW, Rayburn H et al. A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state. J Clin Invest 1998;101:1301-9.
22. Fisher CJ Jr, Yan SB. Protein C levels as a prognostic indicator of outcome in sepsis and related diseases. Crit Care Med 2000;28:S49-S56.
23. Mammen EF. The haematologic manifestations of sepsis. J Antimicrob Chemother 1998;41:17-24.
24. Takano S, Kimura S, Ohdama S, Aoki N. Plasma thrombomodulin in health and diseases. Blood 1990;76:2024-9.
25. Kurosawa S, Stearns-Kurosawa DJ, Carson CW, D'Angelo A, Della Valle P, Esmon CT. Plasma levels of endothelial cell protein C receptor are elevated in patients with sepsis and systemic lupus erythematosus: lack of correlation with thrombomodulin suggests involvment of different pathological processes. Blood 1998;91:725-7.
26. Faust SN, Levin M, Harrison OB, Goldin RD, Lockhart MS, Kondaveeti S et al.. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 2001;345:408-16.
27. White B, Schmidt M, Murphy C, Livingstone W, O'Toole D, Lawler M et al. Activated protein C inhibits lipopolysaccharide-induced nuclear translocation on nuclear factor kB (NF-kB) and tumor necrosis factor a (TNFa) production in the THP-1 monocytic cell line. Br J Haematol 2000;110:130-4.
28. Grey ST, Tsuchida A, Hau H, Orthner CL, Salem HH, Hancock WW. Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-gamma or phorbol esther. J Immunol 1994;153:3664-72.
29. Hancock WW, Grey ST, Hau L, Akalin E, Orthner C, Sayegh MH et al. Binding of activated protein C to a specific receptor on human mononuclear phagocytes inhibits intracellular calcium signalling and monocyte-dependent proliferative responses. Transplantation 1995;60:1525-32.
30. Grey ST, Hancock WW. A physiologic anti-inflammatory pathway based on thrombomodulin expression and generation of activated protein C by human mononuclear phagocytes. J Immunol 1996;156:2256-63.
31. Shu F, Kobayashi H, Fukudome K, Tsuneyoshi N, Kimoto M, Terao T. Activated protein C suppresses tissue factor expression on U937 cells in the endothelial protein C receptor-dependent manner. FEBS Lett 2000;477:208-12.
32. Grinnell BW, Hermann RB, Yan SB. Human protein C inhibits selectin-mediated cell adhesion: role of unique fucosylated oligosaccharide. Glycobiology 1994;2: 221-5.
33. Hirose K, Okajima K, Taoka Y, Uchiba M, Tagami H, Nakano KY et al. Activated protein C reduces the ischemia/reperfusion-induced spinal cord injury in rats by inhibiting neutrophil activation. Ann Surg 2000;232:272-80.
34. Lyseng-Williamson KA, Perry CA. Drotrecogin alfa (activated). Drugs 2002;62:617-30.
35. Bernard GR, Vincent JL, Laterre P-F, La Rosa SP et al. for the Recombinant Human Acitvated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
36. Anti-infective Advisory Committee. FDA Briefing Document: Drotrecogin alfa (activated) (Recombinant human activated protein C (rhAPC)) Xigris. Rockville, MD: Food and Drug Administration, September 12, 2001.
37. Abraham E, Reinhart K, Opal S, Demeyer I et al. for the Optimist Trial Study Group. Efficacy and safety of Tifacogin (Recombinant tissue factor pathway inhihitor) in severe sepsis. JAMA 2003;290:238-47.
38. Warren BL, Eid A, Singer P, Pillay SS et al. for the Kybersept Trial Study Group. Caring for the critically ill patient. High-close antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001;286:1869-78.
39. Giudici D, Baudo F, Palareti G, Ravizza A, Ridolfi L, D'Angelo A. Antithrombin III replacement in patients with sepsis and septic shock. Haematologica 1999; 84:452-60.
40. Murakami K, Okajima K, Uchiba M, Johno M, Nakagaki T, Okabe H et al. Activated protein C attenuates enodtozin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood 1996;87:642-7.
41. Dreyfus M, Magny JF, Brudey F, Schwarz HP, Planche C, Dehan M et al. Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C cocnentrate. N Engl J Med 1991;325: 1565-8.
42. Dreyfus M, Masterson M, David M, Rivard GE, Muller FM, Kreuz W et al. Replacement therapy with a monoclonal antibody purified purified protein C concentrate in newborns with severe congenital protein C deficiency. Semin Thromb Hemost 1995;21:371-81.
43. Muller FM, Ehrenthal W, Hafner G, Schranz D. Purpura fulminans in severe congenital protein C deficiency: monitoring of treatment with protein C concentrate. Eur J Pediatr 1996;155:20-5.
44. Okajima K, Imamura H, Koga S, Inoue M, Takatsuki K, Aoki N. Treatment of patients with disseminated intravascular coagulation by protein C. Am J Hematol 1990;33:277-8.
45. Gerson WT, Dickerman JD, Bovill EG, Golden E. Severe acquired protein C deficiency in purpura fulminans associated with disseminated intravascular coagulation: treatment with protein C concentrate. Pediatrics 1993;91:418-22.
46. Fijnvandraat K, Derkx B, Peters M, Bijlmer R, Sturk A, Prins MH et al. Coagulation activation and tissue necrosis in meningococcal septic shock: severely reduced protein C levels predict a high mortality. Thromb Haemost 1995;73:15-20.
47. Viganò D'Angelo S, Comp PC, Esmon CT, D'Angelo A. Relationship between protein C antigen and anticoagulant activity during oral anticoagulation and in selected disease states. J Clin Invest 1986;77:416-25.
48. Rivard GE, David M, Farrell C, Schwarz HP. Treatment of purpura fulminans in meningococcemia with protein C concentrate. J Pediatr 1995;126:646-52.
49. Rintala E, Seppala OP, Kotilainen P, Pettila V, Rasi V. Protein C in the treatment of coagulopathy in meningococcal disease. Crit Care Med 1998;26:965-8.
50. Smith OP, White B, Vaughan D, Rafferty M, Claffey L, Lyons B et al. Use of protein C concentrate, heparin and haemodiafiltration in meningococcus-induced purpura fulminans. Lancet 1997;350:1590-3.
51. White B, Livingstone W, Murphy C, Hodgson A, Rafferty M, Smith OP. An open-label study of the role adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia. Blood. 2000;96:3719-24.
52. Kreuz W, Veldman A, Escuriola-Ettinghausen C, Schneider W, Beeg T. Protein C concentrate for meningococcal purpura fulminans. Lancet 1998:351:986-7.
53. Ettinghausen CE, Veldman A, Beeg T, Schneider W, Jager G, Kreuz W. Replacement therapy with protein C concentrate in infants and adolescents with meningococcal sepsis and purpura fulminans. Semin Thromb Hemost 1999;25:537-41.
54. Lignell A, Siegbahn A, Stridsberg M, Pauksen K, Gedeborg R, Sjolin J. Low utilisation of unactivated protein C in a patients with meningococcal septic shock and disseminated intravascular coagulation. Acta Anesthesiol Scand 2003;47:897-900.
55. de Kleijn ED, de Groot R, Hack CE, Mulder PG, Engl W, Moritz B et al. Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: a randomized, double-blinded, placebo-controlled, dose-finding study. Crit Care Med 2003;31:1839-47.
56. Fourrier F, Leclerc F, Aidan K, Sadik A, Jourdain M, Tournoys A et al. Combined antithrombin and protein C supplementation in meningococcal purpura fulminans: a pharmacokinetics study. Intensive Care Med 2003;29:1081-7.
57. Kerlin BA, Yan SB, Isermann BH, Brandt JT, Sood R, Basson BR et al. Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia. Blood 2003;102:3085-92.